about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

No­var­tis re­cruits new ex-US leader from Ab­b­Vie as Marie-France Tschudin steps down

Last year
People

Mod­er­na touts broad­er an­ti­body da­ta on up­dat­ed Covid vac­cine as it gears up for fall roll­out

Last year
R&D
Coronavirus

Bio­gen se­cures $1.5B loan to fund Rea­ta buy­out, with three-year re­pay­ment sched­ule baked in

Last year
Financing
Deals

The ne­go­ti­a­tions list is here; Am­gen, Hori­zon clear FTC hur­dle; Fall biotech IPOs?; No­vo buys biotech part­ner in ...

Last year
Weekly

BioN­Tech, Du­al­i­ty­Bio steer ADC in­to PhI­II, with aim to com­pete in HER2-low sub­group with En­her­tu

Last year
R&D

Sanofi taps se­r­i­al biotech in­vestor, en­tre­pre­neur as R&D chief — while pro­mot­ing busi­ness op­er­a­tions, dig­i­tal ...

Last year
People
Pharma

Up­dat­ed: No­vo Nordisk bags new obe­si­ty tar­get in lat­est biotech ac­qui­si­tion, inks R&D deal with spin­out

Last year
Deals

PhI­II fail in Duchenne casts shad­ow over Fi­bro­Gen's top an­ti-fi­brot­ic pro­gram

Last year
R&D

No­var­tis nix­es PhII TGFß an­ti­body — and one-time 'wild card' — af­ter ben­e­fit-risk as­sess­ment

Last year
R&D

FTC paus­es chal­lenge of Am­gen's $28B Hori­zon takeover to con­sid­er set­tle­ment

Last year
Pharma
Law

Rid­ing the wave on lat­est obe­si­ty buy­out; Slack in­ter­view with an­ti-ag­ing re­searcher; Two new IRA law­suits; and more

Last year
Weekly

SPAC merg­er falls through be­tween Wilbur Ross' blank check com­pa­ny and Alzheimer's play­er

Last year
Deals

KRAS late­com­er Roche draws cau­tious com­par­isons to Am­gen, Mi­rati in ear­ly da­ta

Last year
R&D

Roche posts in­ter­im OS da­ta from PhI­II TIG­IT tri­al af­ter leak — and an­a­lysts say it bodes well for fi­nal read­out

Last year
R&D

Apel­lis' safe­ty probe in­to eye drug un­earths is­sues with in­jec­tion kits, while side ef­fects re­main 'very rare'

Last year
R&D
Pharma

Ar­a­vive warns of pos­si­ble liq­ui­da­tion as it ax­es all clin­i­cal work, lays off 70% of em­ploy­ees

Last year
People
R&D

Af­ter two flops, Roche and Ex­elix­is post ear­ly PhI­II win for Tecen­triq/Cabome­tyx com­bo — but will wait for OS da­ta

Last year
R&D
Pharma

No­vo Nordisk and the fu­ture of obe­si­ty drugs; Ex­it Q&A with As­traZeneca's Mene Pan­ga­los; Il­lu­mi­na’s bad week; ...

Last year
Weekly

De­nali, Take­da scrap PhI Alzheimer's drug due to safe­ty sig­nals, 'rapid­ly evolv­ing' land­scape

Last year
R&D

Up­dat­ed: Bay­er cuts PhII or­phan drug as it ups R&D spend­ing, ques­tions swirl around new CEO’s next moves

Last year
R&D

Nek­tar says Eli Lil­ly mis­cal­cu­lat­ed da­ta in eczema tri­al be­fore break­ing off rezpeg part­ner­ship

Last year
R&D

FDA clears Bio­gen, Sage's pill for post­par­tum de­pres­sion; What will Roivant, Bridge­Bio do next?; EQRx be­comes ...

Last year
Weekly

Gala­pa­gos seeks 's­trate­gic op­tion­s' for Jy­s­e­le­ca as JAK in­hibitor sales dis­ap­point again

Last year
Pharma

Play­ground Glob­al, a16z back $26M seed for RNA edit­ing start­up aim­ing to ad­dress mul­ti­ple mu­ta­tions with sin­gle shot

Last year
Financing
Startups
First page Previous page 78910111213 Next page Last page
A service from the Financial Times